Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
|
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [1] Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes
    Edmonston, Daniel
    Lydon, Elizabeth
    Mulder, Hillary
    Chiswell, Karen
    Lampron, Zachary
    Marsolo, Keith
    Goss, Ashley
    Ayoub, Isabelle
    Shah, Raj C.
    Chang, Alexander R.
    Ford, Daniel E.
    Jones, W. Schuyler
    Fonesca, Vivian
    Machineni, Sriram
    Fort, Daniel
    Butler, Javed
    Hunt, Kelly J.
    Pitlosh, Max
    Rao, Ajaykumar
    Ahmad, Faraz S.
    Gordon, Howard S.
    Hung, Adriana M.
    Hwang, Wenke
    Bosworth, Hayden B.
    Pagidipati, Neha J.
    JAMA NETWORK OPEN, 2024, 7 (06) : e2418808
  • [2] Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes
    Skolnik, Neil S.
    Style, Alyssa J.
    DIABETES THERAPY, 2021, 12 (06) : 1613 - 1630
  • [3] Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes
    Neil S. Skolnik
    Alyssa J. Style
    Diabetes Therapy, 2021, 12 : 1613 - 1630
  • [4] Management of type 2 diabetes in chronic kidney disease
    Triozzi, Jefferson L.
    Parker Gregg, L.
    Virani, Salim S.
    Navaneethan, Sankar D.
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [5] Chronic kidney disease screening and renoprotection in type 2 diabetes
    Agaba, E. I.
    Puepet, F. H.
    Ugoya, S. O.
    Agaba, P. A.
    Adabe, R.
    Duguru, M.
    Rowland, A. I.
    ANNALS OF AFRICAN MEDICINE, 2009, 8 (01) : 52 - 54
  • [6] Recommendations for the screening and management of patients with chronic kidney disease
    Rossert, JA
    Wauters, JP
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 : 19 - 28
  • [7] Management of type 2 diabetes mellitus in chronic kidney disease
    Maffioli, Pamela
    Derosa, Giuseppe
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (01) : 95 - 97
  • [8] Prevention and management of chronic kidney disease in type 2 diabetes
    Chadban, S.
    Howell, M.
    Twigg, S.
    Thomas, M.
    Jerums, G.
    Cass, A.
    Campbell, D.
    Nicholls, K.
    Tong, A.
    Mangos, G.
    Stack, A.
    MacIsaac, R. J.
    Girgis, S.
    Colagiuri, R.
    Colagiuri, S.
    Craig, J.
    NEPHROLOGY, 2010, 15 : S162 - S194
  • [9] Screening and diagnosis of chronic kidney disease in people with type 2 diabetes attending Australian general practice
    Manski-Nankervis, Jo-Anne E.
    Thuraisingam, Sharmala
    Lau, Phyllis
    Blackberry, Irene
    Sluggett, Janet K.
    Ilomaki, Jenni
    Bell, J. Simon
    Furler, John
    AUSTRALIAN JOURNAL OF PRIMARY HEALTH, 2018, 24 (03) : 280 - 286
  • [10] Letter to the Editor Regarding “Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes”
    Megha Nataraj
    Arun G. Maiya
    Shankar P. Nagaraju
    Diabetes Therapy, 2022, 13 : 1701 - 1703